Invivyd Inc. (IVVD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Invivyd Inc. (IVVD) has a cash flow conversion efficiency ratio of -0.205x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.71 Million) by net assets ($203.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Invivyd Inc. market capitalisation for the company's overall valuation and market capitalisation.
Invivyd Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Invivyd Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Invivyd Inc. ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Invivyd Inc. to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BVZ Holding AG
SW:BVZN
|
0.079x |
|
HMS Bergbau AG
XETRA:HMU
|
-0.399x |
|
Critical Holdings Berhad
KLSE:0291
|
-0.070x |
|
Next PLC
LSE:NXT
|
0.413x |
|
Chicago Atlantic BDC, Inc.
NASDAQ:LIEN
|
0.000x |
|
Soosan Industries Co. Ltd.
KO:126720
|
0.015x |
|
Camlin Fine Sciences Limited
NSE:CAMLINFINE
|
0.078x |
|
Daewonkangup
KO:000430
|
0.053x |
Annual Cash Flow Conversion Efficiency for Invivyd Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Invivyd Inc. from 2020 to 2025. View today's stock price for Invivyd Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $241.54 Million | $-58.13 Million | -0.241x | +90.47% |
| 2024-12-31 | $67.54 Million | $-170.49 Million | -2.524x | -158.71% |
| 2023-12-31 | $177.47 Million | $-173.16 Million | -0.976x | -57.89% |
| 2022-12-31 | $355.97 Million | $-219.99 Million | -0.618x | -86.67% |
| 2021-12-31 | $558.02 Million | $-184.74 Million | -0.331x | -248.25% |
| 2020-12-31 | $-65.25 Million | $-14.57 Million | 0.223x | -- |
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more